Without insurance, Wegovy lists above thirteen hundred dollars for a month, but the manufacturer’s self-pay program drops that figure substantially for people who qualify, which is the number that actually matters. Ozempic, the diabetes version of the same molecule, sits in a similar list range and is off label for weight loss. Zepbound lists above a thousand dollars with its own cheaper cash program. The real comparison is program to program, not sticker to sticker.
Why is the list price the wrong number to compare?
List prices exist mostly for negotiation between manufacturers, pharmacies, and insurers. Almost no uninsured person pays them. Each of these three drugs now has a direct cash channel that sells below list, and the gaps between those channels are far smaller than the gaps between the sticker figures. Comparing list prices is like comparing hotel rack rates: technically real, rarely paid, and misleading if you plan around them.
So the practical question is not which drug has the lowest list price. It is which self-pay program you qualify for, what it charges at your dose, and whether the price holds month after month. Introductory pricing that resets after a few refills is common enough that the sustainable figure deserves more weight than the first-month figure.
What about the Wegovy pill?
This trips people up constantly. Wegovy is an injectable semaglutide given once weekly. When someone searches for a wegovy pill cost without insurance, they are usually thinking of an oral form. Oral semaglutide for weight management is a distinct product with its own labeling and its own pricing, so its uninsured cost is not interchangeable with the injection price. The FDA overview of semaglutide products lays out how these versions differ, and the distinction affects both coverage and cash price. Anyone quoted a single “Wegovy pill price” should confirm exactly which product is being sold, because the injectable and any oral option are not the same line item. The Wegovy prescribing information describes a subcutaneous injection, not a tablet, which is the clearest way to check what you are actually being offered.
How do the three drugs compare on paper and on price?
| Drug | Approved use | Uninsured reality |
|---|---|---|
| Wegovy (semaglutide) | Chronic weight management | List above $1,300; manufacturer self-pay well below list |
| Ozempic (semaglutide) | Type 2 diabetes | Similar list scale; off label for weight loss, which limits assistance |
| Zepbound (tirzepatide) | Chronic weight management | List above $1,000; its own lower cash self-pay program |
Wegovy and Ozempic share the same active molecule, semaglutide, but they are labeled for different conditions. That labeling difference is why a plan may cover one and not the other for the same person, and why Ozempic’s cash price is often a false economy for weight loss: the off-label use tends to void assistance and coverage that would otherwise apply. Zepbound uses a different molecule, tirzepatide, and competes largely on its self-pay figure.
Do the manufacturer self-pay programs really change the math?
Yes, more than any other factor for uninsured patients. Both Wegovy’s and Zepbound’s makers sell directly to cash payers at prices roughly half of list or lower, depending on dose and enrollment. These programs are the reason a person without coverage can sometimes reach a monthly cost in the mid hundreds rather than four figures. They come with conditions: refill-timing rules, dose-dependent pricing, and enrollment requirements that, if missed, snap the price back toward list.
Ozempic sits awkwardly here. Because it is a diabetes drug, its self-pay and assistance routes are built around diabetes patients, not weight-loss patients. Using it off label for weight loss frequently disqualifies a person from the very programs that would make it affordable, so its apparent price advantage often evaporates.
Where does compounded semaglutide fit for cash payers?
Compounded semaglutide is prepared by a compounding pharmacy rather than manufactured under an approved application. It is not an FDA-approved product, and it has not gone through the process that produced the brand trial evidence. That is a genuine distinction, not fine print. What compounded options often provide is a flat monthly cash price with no insurance involved, which appeals to people the brand programs price out or exclude.
Several supervised telehealth practices publish flat monthly pricing for this route alongside the brand options, and independent cost writeups such as one that compares Walmart cash pricing to program prices can help before any decision; for a Wegovy-focused version you can read the full breakdown and see how the numbers stack against the manufacturer route. Named providers in this space include Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare, and FormBlends is one physician-supervised option among them, with prescribing handled by a licensed clinician rather than sold as a product off a shelf.
The honest framing: compounded medication trades the regulatory assurance behind the brands for a predictable price. Whether that trade is sensible depends on the individual and belongs with a prescriber who knows the case.
Is the cheaper option worth it if the weight comes back?
Price is only half the calculation, because the benefit depends on staying on treatment. The STEP 1 trial extension found that participants regained a large share of lost weight, and saw cardiometabolic gains reverse, after semaglutide was withdrawn. The STEP 4 randomized trial showed continued weekly semaglutide sustained weight loss while switching to placebo led to regain. In the STEP 8 trial, semaglutide produced greater weight loss than daily liraglutide, and STEP 3 showed added benefit when the drug was paired with intensive behavioral therapy.
The lesson for a cost comparison is blunt: the cheapest month is a poor deal if the price forces you to stop, since stopping tends to undo the result. The 2025 obesity pharmacotherapy guideline update treats these medications as long-term therapy, and current work on defining clinical obesity frames them the same way. A sustainable self-pay price beats a low introductory one that you cannot maintain.
Key takeaways
- List prices for all three drugs are misleading; compare self-pay program prices instead.
- Wegovy is an injection, so a pill price is a different product with different cash terms.
- Ozempic is off label for weight loss, which usually strips away its assistance options.
- Compounded semaglutide offers price predictability but is not an FDA-approved product.
- Because regain follows withdrawal, the affordable-long-term price matters most.
See also: Tracing the Paper Trail: What a Certificate of Analysis Actually Proves About IGF-1 LR3
Frequently asked questions
How much does Wegovy cost without insurance?
The list price sits above thirteen hundred dollars for a month of the injectable. Cash payers rarely pay that, because the manufacturer runs a self-pay program that drops the price well below list for people who qualify and stay enrolled.
Is there a Wegovy pill, and what does it cost without insurance?
Wegovy is an injectable semaglutide. An oral semaglutide for weight management is a separate product, so a wegovy pill cost without insurance is not the same as the injection price. Uninsured cost for any oral option depends on the specific approved product and its own self-pay terms.
Is Ozempic cheaper than Wegovy for weight loss?
Ozempic is approved for type 2 diabetes, not weight management, so using it for weight loss is off label and usually not covered for that purpose. Its cash price is similar in scale to Wegovy, and off-label use complicates both coverage and assistance eligibility.
How does Zepbound’s uninsured price compare?
Zepbound also lists above a thousand dollars a month and has its own manufacturer self-pay program at a lower cash figure. The meaningful comparison is between each drug’s self-pay price, not between list prices almost no cash payer actually pays.
Is compounded semaglutide a legitimate way to pay less?
Compounded semaglutide is prepared by a pharmacy and is not an FDA-approved product. It may offer a predictable cash price, but it has not been through the approval process behind the brand trial evidence, which is a real difference a prescriber should weigh.
